Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020000024 - ANTIBACTERIAL TREATMENT USING CANNABINOID COMBINATIONS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1 . A composition comprising a cannabinoid for the treatment or prevention of an infection by a bacterium.

2. The composition of claim 1 further comprising a chelating agent.

3. The composition of claim 1 wherein the composition is a pharmaceutical composition.

4. The composition of claim 1 wherein the infection is a skin infection.

5. The composition of claim 1 wherein the bacterium is:

i. a Gram-positive bacterium;

ii. a bacterium species of a genus selected from the list: Streptococcus spp., Peptostreptococcus spp., Clostridium spp., Listeria spp., Bacillus spp., Staphylococcus spp., Propionibacterium spp., Kocuria spp., and Corynebacterium spp., and combinations thereof;

iii. a biofilm-forming bacterium; and/or

iv. resistant to at least one antibiotic.

6. The composition of claim 1 wherein the cannabinoid is cannabidiol.

7. The composition of claim 2 wherein the chelating agent is EDTA or a pharmaceutically acceptable salt thereof.

8. A method for the treatment or prevention of an infection by a bacterium in a subject in need of such treatment comprising the step of:

administering a therapeutically or preventative effective amount of a composition comprising a cannabinoid.

9. The method of claim 8 wherein the method further comprising:

i. co-administering a chelating agent; or

ii. sequentially administering a chelating agent.

10. The method of claim 8 wherein the infection is a skin infection.

1 1. The method of claim 8 wherein the bacterium is:

i. a Gram-positive bacterium;

ii. a bacterium species of a genus selected from the list: Streptococcus spp., Peptostreptococcus spp., Clostridium spp., Listeria spp., Bacillus spp.,

Staphylococcus spp., Propionibacterium spp., Kocuria spp., and Corynebacte um spp., and combinations thereof;

iii. a biofilm-forming bacterium; and/or

iv. resistant to at least one antibiotic.

12. The method of claim 8 wherein the cannabinoid is cannabidiol.

13. The method of claim 9 wherein the chelating agent is EDTA or a pharmaceutically acceptable salt thereof.

14. Use of a cannabinoid in the manufacture of medicament in the form of a composition for the treatment of an infection by a bacterium of a subject.

15. The use of claim 10 wherein the medicament further comprises a chelating agent.

16. The use of claim 10 wherein the infection is a skin infection.

17. The use of claim 10 wherein the bacterium is:

i. a Gram-positive bacterium;

ii. a bacterium species of a genus selected from the list: Streptococcus spp., Peptostreptococcus spp., Clostridium spp., Listeria spp., Bacillus spp., Staphylococcus spp., Propionibacterium spp., Kocuria spp., and Corynebactehum spp., and combinations thereof;

iii. a biofilm-forming bacterium; and/or

iv. resistant to at least one antibiotic.

18. The use of claim 10 wherein the cannabinoid is cannabidiol.

19. The use of claim 1 1 wherein the chelating agent is EDTA or a pharmaceutically acceptable salt thereof.